Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17853
Title: PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia.
Austin Authors: Di Biase, M A;Zalesky, A;O'keefe, G;Laskaris, L;Baune, B T;Weickert, C S;Olver, James S ;McGorry, P D;Amminger, G P;Nelson, B;Scott, Andrew M ;Hickie, I;Banati, R;Turkheimer, F;Yaqub, M;Everall, I P;Pantelis, C;Cropley, V
Affiliation: Neuroscience Research Australia, Randwick, NSW, Australia
Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia
Schizophrenia Research Institute, Randwick, NSW, Australia
Department of Neuroimaging, King's College London, London, UK
VU University Medical Center, Amsterdam, The Netherlands
Department of Psychiatry, The University of Melbourne, Parkville, VIC Australia
Melbourne School of Engineering, The University of Melbourne, Parkville, VIC Australia
Department of Molecular Imaging and Therapy, The University of Melbourne, Heidelberg, VIC Australia
Department of Medicine, The University of Melbourne, and La Trobe University, Austin Hospital, Heidelberg, Victoria, Australia
Discipline of Psychiatry, The University of Adelaide, Adelaide, SA, Australia
School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia
Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Victoria, Australia
Brain &Mind Centre, The University of Sydney, Camperdown, NSW, Australia
Medical Radiation Sciences, The University of Sydney, Camperdown, NSW, Australia
North Western Mental Health, Melbourne Health, Parkville, Victoria, Australia
Florey Institute for Neurosciences and Mental Health, Parkville, Victoria, Australia
Centre for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton South, Victoria, Australia
Cooperative Research Centre for Mental Health, Carlton, Victoria, Australia
Issue Date: 29-Aug-2017
Date: 2017-08-29
Publication information: Translational psychiatry 2017; 7(8): e1225
Abstract: We examined putative microglial activation as a function of illness course in schizophrenia. Microglial activity was quantified using [11C](R)-(1-[2-chrorophynyl]-N-methyl-N-[1-methylpropyl]-3 isoquinoline carboxamide (11C-(R)-PK11195) positron emission tomography (PET) in: (i) 10 individuals at ultra-high risk (UHR) of psychosis; (ii) 18 patients recently diagnosed with schizophrenia; (iii) 15 patients chronically ill with schizophrenia; and, (iv) 27 age-matched healthy controls. Regional-binding potential (BPND) was calculated using the simplified reference-tissue model with four alternative reference inputs. The UHR, recent-onset and chronic patient groups were compared to age-matched healthy control groups to examine between-group BPND differences in 6 regions: dorsal frontal, orbital frontal, anterior cingulate, medial temporal, thalamus and insula. Correlation analysis tested for BPND associations with gray matter volume, peripheral cytokines and clinical variables. The null hypothesis of equality in BPND between patients (UHR, recent-onset and chronic) and respective healthy control groups (younger and older) was not rejected for any group comparison or region. Across all subjects, BPND was positively correlated to age in the thalamus (r=0.43, P=0.008, false discovery rate). No correlations with regional gray matter, peripheral cytokine levels or clinical symptoms were detected. We therefore found no evidence of microglial activation in groups of individuals at high risk, recently diagnosed or chronically ill with schizophrenia. While the possibility of 11C-(R)-PK11195-binding differences in certain patient subgroups remains, the patient cohorts in our study, who also displayed normal peripheral cytokine profiles, do not substantiate the assumption of microglial activation in schizophrenia as a regular and defining feature, as measured by 11C-(R)-PK11195 BPND.
URI: https://ahro.austin.org.au/austinjspui/handle/1/17853
DOI: 10.1038/tp.2017.193
Journal: Translational psychiatry
PubMed URL: 28850113
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Nov 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.